Lataa...
Hydroxyurea therapy for sickle cell anemia
INTRODUCTION: Sickle cell anemia (SCA) is a severe, inherited hemoglobin disorder affecting 100,000 persons in the US and millions worldwide. Hydroxyurea, a once daily oral medication, has emerged as the primary disease-modifying therapy for SCA. The accumulated body of evidence over 30 years demons...
Tallennettuna:
| Julkaisussa: | Expert Opin Drug Saf |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5868345/ https://ncbi.nlm.nih.gov/pubmed/26366626 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14740338.2015.1088827 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|